RBC Capital Keeps Their Buy Rating on Johnson & Johnson (JNJ)
In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), ...
RBC Capital cuts AG Growth stock rating, slashes price target
RBC Capital Markets adjusted its stance on AG Growth International Inc (AFN:CN) (OTC: AGGZF), downgrading the stock from Outperform to Sector Perform and significantly reducing the price target to ...
RBC Capital Keeps Their Hold Rating on Incyte (INCY)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.
Hosted on MSN9h
RBC Capital Downgrades Intra-Cellular Therapies (ITCI)
Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...
RBC Capital scoffs at critics with Carvana upgrade
Financial writer discusses RBC Capital's bullish outlook on Carvana, citing upside potential in retail unit estimates and path to durable free cash flow.
bovnews17h
Why Did RBC Capital Mkts Give CF Industries Holdings, Inc. (CF) Stock Sector Perform Rating?
CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...
bovnews18h
What’s Fueling Aramark (ARMK) Stock’s 7.97% Gain Above Its 200-Day SMA?
On Tuesday, Aramark (ARMK) stock saw a decline, ending the day at $38.59 which represents a decrease of $-0.57 or -1.46% from the prior close of $39.16. The stock opened at $39.46 and touched a low of ...
Yahoo Finance16d
Carvana stock jumps as RBC lifts rating to Buy
Investing.com -- RBC Capital Markets on Monday upgraded Carvana (NYSE:CVNA) shares to Outperform, and lifted the target price to $280 from $270. According to the firm’s analysts, following ...
Hochschild Mining Shares Tumble on 2025 Capital Expenditure, Cost Guidance
However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...
RBC Capital下调Intra-Cellular股票评级，目标价上调至132美元
周二，RBC Capital Markets调整了对Intra-Cellular Therapies股票的立场，将这家生物制药公司的评级从"跑赢大市"下调至"与大市同步"。然而，该公司将股票目标价从之前的108美元上调至132美元。这一调整是在上周强生公司 (JNJ)宣布计划以约146亿美元收购Intra-Cellular Therapies之后做出的。
RBC helps students expand their career horizons
Each year, RBC supports thousands of students from different educational backgrounds in exploring various career paths within ...
RBC Capital下调CF Industries股票评级，估值问题引发担忧
在其他近期新闻中，CF Industries经历了一系列重大发展和分析师关注。Piper Sandler将CF Industries的股票评级从减持上调至增持，理由是谷物价格上涨。这次上调主要是由于谷物和化肥价格之间的强相关性，暗示主要农业地区的化肥需求可能上升。此外，Piper Sandler将CF Industries的目标价上调至79美元，而RBC ...